1Fischl MA, Richman DD, Grieco MH, et al.The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex.A double-blind, placebo-controlled tria[ J ]. N Engl J Med, 1987,317(4):185 - 191.
2Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine(AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV)infection. A doubleblind, placebo-controlled trial.The AIDS Clinical Trials Group [ J]. Ann Intern Med, 1990,112(10) : 727 - 737.
3Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals.Delta Coordinating Committee [ J ]. Lancet, 1996,348 (9023) : 283 - 291.
4Schooley RT, Ramirez-Ronda C, Lange JM, et al.Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group[J]. J Infect Dis, 1996,173(6) : 1354 - 1366.
5Chun TW, Fauei AS. Latent reservoris of HIV: obstacles to the eradication of virus[J]. Proc Natl Acad Sci U S A, 1999,96(20) : 10958 - 10961.
6Chun TW, Davey RT, Engel D, et al. Re- emergence of HIV after stopping therapy [ J ]. Nature, 1999,401 (6756) : 874 - 875.
7Marzolini C, Telenti A, Decosterd LA, et al.Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV infected patients[ J ]. AIDS, 2001,13 : 71 - 75.
8Brinkman Kter, Hofstede H J, Burger D M, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway[J]. AIDS, 1998,12 : 1735 - 1744.
9Carr A, Morey A, Mallon, et al. Fatal portal hypertension, liver failure and mitochondrial dysfunction after HIV-1 nucleoside analogue induced hepatitisandlacticacidaemia [ J ] .Lancet, 2001, 357:1412 - 1414.
10Yarasheki KE,Tebas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitor associated diabetes [ J ]. J Acquir Immune Deficysyndr, 1999,21:209 - 216.
9Maggiolo F,Ripamonti D,Gregis G,et al.Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells:a controlled,prospective trial.AIDS,2004,18 (3):439-446.
10Carcelain G,Tubiana R,Samri A,et al.Transient mobilization of human immunodeficiency virus (HIV) -specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.J Virol,2001,75(1):234-241.
